$114.66
2.35%
NYSE, Mon, Nov 25 2024
ISIN
US7140461093
Symbol
PKI

PerkinElmer Stock price

$114.66
-1.67 1.44% 1M
+1.39 1.23% 6M
+5.35 4.89% YTD
+26.41 29.93% 1Y
-62.29 35.20% 3Y
+22.56 24.50% 5Y
+68.90 150.57% 10Y
NYSE, Closing price Mon, Nov 25 2024
+2.63 2.35%
ISIN
US7140461093
Symbol
PKI
Sector

Key metrics

Market capitalization $13.95b
Enterprise Value $16.04b
P/E (TTM) P/E ratio 46.59
EV/FCF (TTM) EV/FCF 28.42
EV/Sales (TTM) EV/Sales 5.89
P/S ratio (TTM) P/S ratio 5.13
P/B ratio (TTM) P/B ratio 1.77
Dividend yield 0.24%
Last dividend (FY24) $0.28
Revenue growth (TTM) Revenue growth -2.66%
Revenue (TTM) Revenue $2.72b
EBIT (operating result TTM) EBIT $377.58m
Free Cash Flow (TTM) Free Cash Flow $564.37m
Cash position $1.23b
EPS (TTM) EPS $2.46
P/E forward 52.84
P/S forward 5.06
EV/Sales forward 5.82
Short interest 3.57%
Show more

Is PerkinElmer a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

PerkinElmer Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a PerkinElmer forecast:

12x Buy
57%
8x Hold
38%
1x Sell
5%

Analyst Opinions

21 Analysts have issued a PerkinElmer forecast:

Buy
57%
Hold
38%
Sell
5%

Financial data from PerkinElmer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,722 2,722
3% 3%
100%
- Direct Costs 1,302 1,302
1% 1%
48%
1,419 1,419
6% 6%
52%
- Selling and Administrative Expenses 416 416
4% 4%
15%
- Research and Development Expense 197 197
11% 11%
7%
806 806
9% 9%
30%
- Depreciation and Amortization 428 428
1% 1%
16%
EBIT (Operating Income) EBIT 378 378
16% 16%
14%
Net Profit 304 304
60% 60%
11%

In millions USD.

Don't miss a Thing! We will send you all news about PerkinElmer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.

Head office United States
CEO Prahlad Singh
Employees 11,500
Founded 1937
Website www.revvity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today